These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 2364157)

  • 1. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
    Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1990 Mar; 109(3):290-2. PubMed ID: 2364157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of finoptin on the accumulation of doxorubicin in leukemia P388 cells with induced resistance to the antibiotic].
    Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM
    Biull Eksp Biol Med; 1989 Dec; 108(12):714-6. PubMed ID: 2634447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
    Donenko FV; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verapamil effect on the accumulation of doxorubicin in the leukemia P388 cells with induced antibiotic resistance.
    Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM
    Arch Geschwulstforsch; 1990; 60(2):129-32. PubMed ID: 2339961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells.
    Noviello E; Allievi E; Russo P; Parodi S
    Anticancer Drug Des; 1997 Jun; 12(4):261-76. PubMed ID: 9199659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in glutathione-S-transferase activity during induction of resistance of leukemia P 388 and Ehrlich ascitic tumor cells to doxorubicin].
    Donenko FV; Kabieva AO; Borovkova NB; Moroz LV
    Biull Eksp Biol Med; 1991 Aug; 112(8):188-90. PubMed ID: 1786387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity to anthracyclines in P388/dx leukaemia cells.
    Bossa R; Dasdia T; Galatulas I; Zunino F
    Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
    Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
    J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
    Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
    Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Treat Rep; 1985 May; 69(5):523-5. PubMed ID: 4005874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
    Inaba M; Maruyama E
    Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circumvention of drug resistance of P388/R cells by the combination of adriamycin and mitoxantrone with hyperthermia (42 degrees C).
    Juvekar AS; Chitnis MP
    Neoplasma; 1991; 38(2):207-11. PubMed ID: 2041579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo response of mitoxantrone and doxorubicin with dipyrone in parental and doxorubicin-resistant P388 leukemia.
    Kamath NS; Chitnis MP
    Oncology; 1990; 47(2):166-9. PubMed ID: 2314829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of murine testicular leukemia.
    Hoots WK; Nelson JA
    Cancer Res; 1984 Jun; 44(6):2464-6. PubMed ID: 6722788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of antitumor activity of pirarubicin by chlorpromazine in mice bearing doxorubicin-resistant P388 leukemia.
    Shibata H; Maekawa I; Furusawa S; Kawauchi H; Takayanagi Y; Sasaki K
    Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):359-62. PubMed ID: 2093213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice].
    Dai ZQ; Xu JY; Yuan XJ; Cai JC
    Zhongguo Yao Li Xue Bao; 1996 Jan; 17(1):69-71. PubMed ID: 8737460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of DMDP, a tiapamil analogue, on adriamycin efflux in adriamycin-resistant and -sensitive P388 cells.
    Radel S; Mayhew E; Rustum YM
    Anticancer Res; 1987; 7(6):1105-8. PubMed ID: 3442407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM; Goldenberg S; Gottesman MM; Hait WN
    Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
    Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
    Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.